MedPal AI gets FDA approval for Mounjaro heart protection
MedPal AI PLC said the FDA approved tirzepatide (Mounjaro) to cut the risk of heart attack and stroke in type 2 diabetes, expanding its GLP-1 market reach.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.